SPP1 and ischemia: Interestingly, in an ischemia model, intranasal delivery of a SPP1/OPN peptide suppressed microglial activation and the release of pro-inflammatory cytokines IL-1β and IL-6, an indication of reduced NLRP3 activity (121).